SANTA MONICA, Calif., Feb. 20 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com) focused on bringing the life saving potential of stem cells to families nationwide and internationally, today announced that Matthew Schissler, founder and CEO, in an interview with analyst Francis Gaskins, provided details of the Company's special shareholder meeting in March.
The complete interview is available at: http://www.stoxrox.com/cbai-2-18-09-e.mp3
In the interview, Mr. Schissler explains why the Company is asking for an increase in authorized shares. He explains that authorized is "vastly different from outstanding" and the Company currently has no commitments or understandings for the issuance of additional outstanding shares other than those currently on file at the SEC.
"Our goal is to be ahead of the game. We want to grow the Company into a global leader in the storage of stem cells and that includes the ability to act and react quickly. We also want to benefit from what we believe will be greatly increased research in this sector. This lets us control our destiny," Mr. Schissler said. Asked why Cord Blood America is asking for such a large increase in authorized shares, the Company's founder said "this is a time-consuming, costly process and we only want to do it once in the Company's history."
About Cord Blood America
Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasi
|SOURCE Cord Blood America, Inc.|
Copyright©2009 PR Newswire.
All rights reserved